JP2025501028A5 - - Google Patents
Info
- Publication number
- JP2025501028A5 JP2025501028A5 JP2024538272A JP2024538272A JP2025501028A5 JP 2025501028 A5 JP2025501028 A5 JP 2025501028A5 JP 2024538272 A JP2024538272 A JP 2024538272A JP 2024538272 A JP2024538272 A JP 2024538272A JP 2025501028 A5 JP2025501028 A5 JP 2025501028A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- sequence
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293242P | 2021-12-23 | 2021-12-23 | |
| US63/293,242 | 2021-12-23 | ||
| PCT/US2022/082214 WO2023122714A2 (en) | 2021-12-23 | 2022-12-22 | Compositions and methods for treatment of thyroid eye disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501028A JP2025501028A (ja) | 2025-01-16 |
| JP2025501028A5 true JP2025501028A5 (https=) | 2026-01-05 |
Family
ID=86903795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538272A Pending JP2025501028A (ja) | 2021-12-23 | 2022-12-22 | 甲状腺眼疾患を治療するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240352133A1 (https=) |
| EP (1) | EP4453036A2 (https=) |
| JP (1) | JP2025501028A (https=) |
| KR (1) | KR20240117639A (https=) |
| CN (1) | CN118742567A (https=) |
| AU (1) | AU2022420605A1 (https=) |
| CA (1) | CA3240723A1 (https=) |
| MX (1) | MX2024007968A (https=) |
| WO (1) | WO2023122714A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220267450A1 (en) | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| EP4384219A4 (en) | 2021-08-10 | 2025-06-18 | Viridian Therapeutics, Inc. | COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE |
| US20230406942A1 (en) * | 2022-06-10 | 2023-12-21 | Horizon Therapeutics Ireland Dac | Igf1r antibodies |
| AU2024287547A1 (en) | 2023-07-07 | 2026-01-22 | Viridian Therapeutics, Inc. | Methods of treating chronic thyroid eye disease |
| TW202519262A (zh) * | 2023-09-06 | 2025-05-16 | 美商維里迪恩醫療股份有限公司 | 抗ｉｇｆ－１ｒ抗體之醫藥組合物 |
| US20250197511A1 (en) * | 2023-12-13 | 2025-06-19 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease |
| WO2025136985A1 (en) * | 2023-12-17 | 2025-06-26 | Viridian Therapeutics, Inc. | Compositions, doses, and methods for treatment of thyroid eye disease |
| WO2026055673A1 (en) * | 2024-09-09 | 2026-03-12 | Viridian Therapeutics, Inc. | Methods for treatment of thyroid eye disease with an anti-igf-1r antibody |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR046071A1 (es) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
-
2022
- 2022-12-22 WO PCT/US2022/082214 patent/WO2023122714A2/en not_active Ceased
- 2022-12-22 CN CN202280091368.6A patent/CN118742567A/zh active Pending
- 2022-12-22 EP EP22912727.9A patent/EP4453036A2/en active Pending
- 2022-12-22 CA CA3240723A patent/CA3240723A1/en active Pending
- 2022-12-22 JP JP2024538272A patent/JP2025501028A/ja active Pending
- 2022-12-22 KR KR1020247024194A patent/KR20240117639A/ko active Pending
- 2022-12-22 MX MX2024007968A patent/MX2024007968A/es unknown
- 2022-12-22 AU AU2022420605A patent/AU2022420605A1/en active Pending
-
2024
- 2024-06-21 US US18/749,821 patent/US20240352133A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025501028A5 (https=) | ||
| JP2025503339A5 (https=) | ||
| JP2025503614A5 (https=) | ||
| US12528876B2 (en) | CD73 blocking antibodies | |
| EP2768855B1 (en) | Stable multiple antigen-binding antibody | |
| US12325745B2 (en) | Anti-DLL3 antibodies and uses thereof | |
| CN119679936A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| CA3118777A1 (en) | Methods of treating graves' ophthalmopathy using anti-fcrn antibodies | |
| EP4095158A1 (en) | Pharmaceutical composition containing anti-btla antibody and use thereof | |
| JP2024510142A5 (https=) | ||
| CN115698074A (zh) | 抗-cd98抗体和其用途 | |
| WO2018183182A1 (en) | Methods and compositions for reduction of immunogenicity | |
| TW202037365A (zh) | 抗IL17a抗體的水性藥物組合物及其用途 | |
| CN114762678A (zh) | 抗tigit抗体药物组合物及其用途 | |
| WO2017059813A1 (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| JP2026001077A5 (https=) | ||
| CN120603852A (zh) | 一种fap/cd40结合分子的药物组合物及其医药用途 | |
| JP2024542158A5 (https=) | ||
| JP2023502398A5 (https=) | ||
| CN118382463A (zh) | 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途 | |
| JP2024538140A5 (https=) | ||
| WO2022184148A1 (zh) | Il-21-抗白蛋白单域抗体融合蛋白药物组合物及其用途 | |
| US20240383990A1 (en) | Hinge-modified bispecific antibodies | |
| CN116440263A (zh) | 抗ctla-4抗体药物组合物及其用途 | |
| US20230203171A1 (en) | Aqueous pharmaceutical composition of levilimab |